Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 3/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL648491 | 0.89 | IDO1 (0.44) | MAPTNPSR1KDM4ETDP1IDO1 | |
| SCHEMBL20878106 | 0.84 | KCNN4 (0.42) | GABRA1GABRB2L3MBTL1MAPTNPSR1 | |
| Methoxymethane SCHEMBL27728603 | 0.84 | GABRA1 (0.50) | GABRA1GABRB2L3MBTL1MAPTNPSR1 | |
| SCHEMBL22711438 | 0.83 | IDO1 (0.40) | MAPTNPSR1KDM4ETDP1IDO1 | |
| SCHEMBL2792022 | 0.82 | GABRA1 (0.44) | GABRA1GABRB2L3MBTL1MAPTNPSR1 | |
| SCHEMBL498530 | 0.82 | GABRA1 (0.44) | GABRA1GABRB2L3MBTL1MAPTNPSR1 | |
| SCHEMBL8439589 | 0.81 | ADRA2A (0.47) | HPGDIDO1SMN1; SMN2PDK2FFAR1 | |
| SCHEMBL18892799 | 0.81 | NPSR1 (0.37) | L3MBTL1MAPTNPSR1IDO1CASP1 | |
| SCHEMBL25425763 | 0.81 | GABRA1 (0.58) | GABRA1GABRB2L3MBTL1MAPTNPSR1 | |
| SCHEMBL36294 | 0.81 | GABRA1 (0.58) | GABRA1GABRB2L3MBTL1MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239934-A1 | FUMARIC ACID DIESTER RESIN, FILM AND POLARIZING PLATE | TOSOH CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239934-A1 | FUMARIC ACID DIESTER RESIN, FILM AND POLARIZING PLATE | TOSOH CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| US-20220409734-A1 | ANTIBODY DRUG CONJUGATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-12-29 | — | — | US | disclosed |
| US-11344549-B2 | 2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2022-05-31 | — | — | US | disclosed |
| US-20210077489-A1 | 2-SUBSTITUTED PYRAZOLE AMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION, AND APPLICATION THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2021-03-18 | — | — | US | disclosed |
| US-10927096-B2 | Ester substituted ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10927125-B2 | Substituted cinnolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2021-02-23 | — | — | US | disclosed |
| US-20210002254-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-01-07 | — | — | US | disclosed |
| US-20200290991-A1 | ESTER SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. | 2020-09-17 | — | — | US | disclosed |
| US-7288659-B2 | Acylaminothiazole derivatives, their preparation and therapeutic use | SANOFI-AVENTIS (FR) | 2007-10-30 | — | — | US | disclosed |
| US-7271270-B2 | High affinity small molecule C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-20040152736-A1 | Thrombin receptor antagonists | TOPROL ACQUISITION LLC | 2004-08-05 | — | — | US | disclosed |
| EP-0523697-B1 | Color-developing compositions and their use | MITSUI TOATSU CHEMICALS (JP) | 1997-04-02 | — | — | EP | disclosed |
| EP-0268878-B1 | Salicylic acid copolymers and their metal salts, production process thereof, color-developing agents comprising metal salts of the copolymers and color-developing sheets employing the agents | MITSUI TOATSU CHEMICALS (JP) | 1996-01-31 | — | — | EP | disclosed |
| US-5447901-A | Color-developing sheet: base material coated with composition of /a/ multivalent metal-modified salicylic acid resin formed from salicylic acid, a benzyl compound and optional styrene and /b/ analogous resin free of salicylic acid | MITSUI TOATSU CHEMICAL, INC. (JP) | 1995-09-05 | — | — | US | disclosed |
| US-5376615-A | Pressure sensitive elements containing a salicylic acid resin and a phenolic resin | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1994-12-27 | — | — | US | disclosed |
| EP-0523697-A1 | Color-developing compositions and their use | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1993-01-20 | — | — | EP | disclosed |
| US-5023366-A | Reacted with a benzyl halide, alcohol or ether; for pressure sensitive elements | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1991-06-11 | — | — | US | disclosed |
| EP-0268878-A2 | Salicylic acid copolymers and their metal salts, production process thereof, color-developing agents comprising metal salts of the copolymers and color-developing sheets employing the agents | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1988-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210077489-A1 | 2-SUBSTITUTED PYRAZOLE AMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION, AND APPLICATION THEREOF | JAK1, JAK3, JAK2 | GABRA1 1689/4885GABRB2 1847/4885L3MBTL1 4659/4885 |
| US-10927125-B2 | Substituted cinnolines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | GABRA1 4467/4885GABRB2 4301/4885L3MBTL1 1252/4885 |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | GABRA1 2882/4885GABRB2 4079/4885L3MBTL1 914/4885 |
| US-20040152736-A1 | Thrombin receptor antagonists | CNR1, TBXA2R, CNR2 | GABRA1 108/4885GABRB2 232/4885L3MBTL1 4370/4885 |
| US-10927096-B2 | Ester substituted ion channel blockers and methods for use | TRPV1, TRPA1, TRPV2 | GABRA1 548/4885GABRB2 331/4885L3MBTL1 4810/4885 |
| US-20210002254-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | GABRA1 194/4885GABRB2 133/4885L3MBTL1 4237/4885 |
| US-20220409734-A1 | ANTIBODY DRUG CONJUGATES | STING1, CGAS, TBK1 | GABRA1 720/4885GABRB2 1257/4885L3MBTL1 4082/4885 |
| US-11344549-B2 | 2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof | JAK1, JAK3, JAK2 | GABRA1 1689/4885GABRB2 1847/4885L3MBTL1 4659/4885 |
| US-20200290991-A1 | ESTER SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPA1, TRPV2 | GABRA1 548/4885GABRB2 331/4885L3MBTL1 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.